Pasquale Pagliaro

List of Publications by Year in Descending Order

161 papers	5,481 citations	41 h-index	67 g-index
181 ext. papers	6,336 ext. citations	5.6 avg, IF	5.82 L-index

#	Paper	IF	Citations
161	A TRICk to Improve the Effectiveness of RIC: Role of Limb Temperature in Enhancing the Effectiveness of Remote Ischemic Conditioning.. *Biology*, **2022**, 11,	4.9	2
160	Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity?. *Journal of Clinical Medicine*, **2022**, 11,	5.1	4
159	Angiotensin-converting enzyme 2: a key enzyme in key organs. *Journal of Cardiovascular Medicine*, **2022**, 23, 1-11	1.9	1
158	Janus, or the inevitable battle between too much and too little oxygen.. *Antioxidants and Redox Signaling*, **2022**,	8.4	2
157	Challenges facing the clinical translation of cardioprotection: 35 years after the discovery of ischemic preconditioning.. *Vascular Pharmacology*, **2022**, 106995	5.9	2
156	Aging, sex and NLRP3 inflammasome in cardiac ischaemic disease. *Vascular Pharmacology*, **2022**, 145, 107001	5.9	1
155	Regulation of STAT3 and its role in cardioprotection by conditioning: focus on non-genomic roles targeting mitochondrial function. *Basic Research in Cardiology*, **2021**, 116, 56	11.8	12
154	Understanding the heart-brain axis response in COVID-19 patients: A suggestive perspective for therapeutic development. *Pharmacological Research*, **2021**, 168, 105581	10.2	12
153	Extracellular vesicles from patients with Acute Coronary Syndrome impact on ischemia-reperfusion injury. *Pharmacological Research*, **2021**, 170, 105715	10.2	5
152	Validation and Reliability of a Novel Vagus Nerve Neurodynamic Test and Its Effects on Heart Rate in Healthy Subjects: Little Differences Between Sexes. *Frontiers in Neuroscience*, **2021**, 15, 698470	5.1	0
151	Ischemic heart disease and cardioprotection: Focus on estrogenic hormonal setting and microvascular health. *Vascular Pharmacology*, **2021**, 141, 106921	5.9	2
150	Percutaneous Coronary Intervention (PCI) Reprograms Circulating Extracellular Vesicles from ACS Patients Impairing Their Cardio-Protective Properties. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
149	IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. *Basic Research in Cardiology*, **2021**, 116, 52	11.8	11
148	Extracellular vesicles (EVs) in ischemic conditioning and angiogenesis: Focus on endothelial derived EVs. *Vascular Pharmacology*, **2021**, 140, 106873	5.9	7
147	Extracellular Vesicles in Comorbidities Associated with Ischaemic Heart Disease: Focus on Sex, an Overlooked Factor. *Journal of Clinical Medicine*, **2021**, 10,	5.1	3
146	Physical activity/inactivity and COVID-19. *European Journal of Preventive Cardiology*, **2020**,	3.9	14
145	COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. *GeroScience*, **2020**, 42, 1021-1049	8.9	78

144	Mitochondrial and mitochondrial-independent pathways of myocardial cell death during ischaemia and reperfusion injury. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 3795-3806	5.6	56
143	Is macrophages heterogeneity important in determining COVID-19 lethality?. *Medical Hypotheses*, **2020**, 143, 110073	3.8	15
142	ACE/ACE2 Ratio: A Key Also in 2019 Coronavirus Disease (Covid-19)?. *Frontiers in Medicine*, **2020**, 7, 335	4.9	38
141	Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols. *British Journal of Pharmacology*, **2020**, 177, 5312-5335	8.6	40
140	Diabetic Cardiomyopathy and Ischemic Heart Disease: Prevention and Therapy by Exercise and Conditioning. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	20
139	Obesity and Cardioprotection. *Current Medicinal Chemistry*, **2020**, 27, 230-239	4.3	10
138	The Inflammatory Cytokine IL-3 Hampers Cardioprotection Mediated by Endothelial Cell-Derived Extracellular Vesicles Possibly via Their Protein Cargo. *Cells*, **2020**, 10,	7.9	8
137	Back and forth from basic science to clinical translation. *Minerva Anestesiologica*, **2020**, 86, 890-891	1.9	1
136	Extracellular vesicles and cardiovascular system: Biomarkers and Cardioprotective Effectors. *Vascular Pharmacology*, **2020**, 135, 106790	5.9	25
135	Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades. *Oxidative Medicine and Cellular Longevity*, **2020**, 2020, 9219825	6.7	10
134	Sex-related differences in COVID-19 lethality. *British Journal of Pharmacology*, **2020**, 177, 4375-4385	8.6	36
133	Cardioprotection of PLGA/gelatine cardiac patches functionalised with adenosine in a large animal model of ischaemia and reperfusion injury: A feasibility study. *Journal of Tissue Engineering and Regenerative Medicine*, **2019**, 13, 1253-1264	4.4	9
132	Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy. *Current Clinical Pathology*, **2019**, 3-14	0.1	
131	Molecular Mechanisms of Cardiovascular Damage Induced by Anti-HER-2 Therapies. *Current Clinical Pathology*, **2019**, 15-19	0.1	
130	Redox Aspects of Myocardial Ischemia/Reperfusion Injury and Cardioprotection **2019**, 289-324		0
129	Innate immunity as a target for acute cardioprotection. *Cardiovascular Research*, **2019**, 115, 1131-1142	9.9	70
128	Circulating blood cells and extracellular vesicles in acute cardioprotection. *Cardiovascular Research*, **2019**, 115, 1156-1166	9.9	67
127	Hemodynamic abnormalities during muscle metaboreflex activation in patients with type 2 diabetes mellitus. *Journal of Applied Physiology*, **2019**, 126, 444-453	3.7	8

126	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. *Antioxidants and Redox Signaling*, **2019**, 30, 2110-2153	8.4	73
125	Apelin-induced cardioprotection against ischaemia/reperfusion injury: roles of epidermal growth factor and Src. *Acta Physiologica*, **2018**, 222, e12924	5.6	15
124	Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. *Frontiers in Physiology*, **2018**, 9, 167	4.6	74
123	Redox Aspects of Chaperones in Cardiac Function. *Frontiers in Physiology*, **2018**, 9, 216	4.6	11
122	Mitochondria in Cardiac Postconditioning. *Frontiers in Physiology*, **2018**, 9, 287	4.6	14
121	Notch1 Mediates Preconditioning Protection Induced by GPER in Normotensive and Hypertensive Female Rat Hearts. *Frontiers in Physiology*, **2018**, 9, 521	4.6	22
120	Cardioprotective Properties of Human Platelets Are Lost in Uncontrolled Diabetes Mellitus: A Study in Isolated Rat Hearts. *Frontiers in Physiology*, **2018**, 9, 875	4.6	14
119	Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. *Basic Research in Cardiology*, **2018**, 113, 39	11.8	224
118	Cyclodextrin and Cyclodextrin Polymers as Oxygen Nanocarriers to Limit Hypoxia/Reoxygenation Injury: Implications from an In Vitro Model. *Polymers*, **2018**, 10,	4.5	18
117	Silica nanoparticles actively engage with mesenchymal stem cells in improving acute functional cardiac integration. *Nanomedicine*, **2018**, 13, 1121-1138	5.6	14
116	Metaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome. *Current Medicinal Chemistry*, **2018**, 25, 1294-1310	4.3	35
115	Role of NLRP-3 Inflammasome in Hypertension: A Potential Therapeutic Target. *Current Pharmaceutical Biotechnology*, **2018**, 19, 708-714	2.6	32
114	Nanoprecipitated catestatin released from pharmacologically active microcarriers (PAMs) exerts pro-survival effects on MSC. *International Journal of Pharmaceutics*, **2017**, 523, 506-514	6.5	
113	Myocardial ischemia/reperfusion upregulates the transcription of the Neuregulin1 receptor ErbB3, but only postconditioning preserves protein translation: Role in oxidative stress. *International Journal of Cardiology*, **2017**, 233, 73-79	3.2	11
112	Hypertension, hypertrophy, and reperfusion injury. *Journal of Cardiovascular Medicine*, **2017**, 18, 131-135	1.9	16
111	Cardioprotective effects of calcitonin gene-related peptide in isolated rat heart and in H9c2 cells via redox signaling. *Biomedicine and Pharmacotherapy*, **2017**, 90, 194-202	7.5	8
110	Obestatin regulates cardiovascular function and promotes cardioprotection through the nitric oxide pathway. *Journal of Cellular and Molecular Medicine*, **2017**, 21, 3670-3678	5.6	21
109	Platelets, diabetes and myocardial ischemia/reperfusion injury. *Cardiovascular Diabetology*, **2017**, 16, 71	8.7	42

108	Chromogranin A-Derived Peptides in Cardiac Pre- and Post-conditioning. *UNIPA Springer Series*, **2017**, 169-193	0.1	
107	Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S76-83	1.9	22
106	Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S64-75	1.9	18
105	Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways. *Oxidative Medicine and Cellular Longevity*, **2016**, 2016, 5271251	6.7	61
104	Maladaptive Modulations of NLRP3 Inflammasome and Cardioprotective Pathways Are Involved in Diet-Induced Exacerbation of Myocardial Ischemia/Reperfusion Injury in Mice. *Oxidative Medicine and Cellular Longevity*, **2016**, 2016, 3480637	6.7	35
103	Pathophysiology of anthracycline cardiotoxicity. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S3-S11	1.9	25
102	Role of biomarkers in monitoring antiblastic cardiotoxicity. *Journal of Cardiovascular Medicine*, **2016** , 17 Suppl 1, S27-34	1.9	17
101	A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S84-92	1.9	39
100	A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S93-S104	1.9	31
99	Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology. *International Journal of Cardiology*, **2015**, 191, 203-10	3.2	25
98	Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. *Heart Failure Reviews*, **2015**, 20, 621-31	5	32
97	Preconditioning cardioprotection and exercise performance: a radical point of view. *Sport Sciences for Health*, **2015**, 11, 137-151	1.3	6
96	Redox signalling and cardioprotection: translatability and mechanism. *British Journal of Pharmacology*, **2015**, 172, 1974-95	8.6	56
95	A comparative study of myocardial molecular phenotypes of two tfr2□hull mice: role in ischemia/reperfusion. *BioFactors*, **2015**, 41, 360-71	6.1	10
94	Effects of bone marrow mesenchymal stem cells (BM-MSCs) on rat pial microvascular remodeling after transient middle cerebral artery occlusion. *Frontiers in Cellular Neuroscience*, **2015**, 9, 329	6.1	5
93	Effects of Physical Exercise on Cardiovascular Diseases: Biochemical, Cellular, and Organ Effects. *BioMed Research International*, **2015**, 2015, 853632	3	2
92	Human mesenchymal stem cells labelled with dye-loaded amorphous silica nanoparticles: long-term biosafety, stemness preservation and traceability in the beating heart. *Journal of Nanobiotechnology*, **2015**, 13, 77	9.4	14
91	Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC). *Current Drug Targets*, **2015**, 16, 895-903	3	23

90	Endogenous Cardioprotective Agents: Role in Pre and Postconditioning. *Current Drug Targets*, **2015**, 16, 843-67	3	27
89	The effect of bioartificial constructs that mimic myocardial structure and biomechanical properties on stem cell commitment towards cardiac lineage. *Biomaterials*, **2014**, 35, 92-104	15.6	22
88	Protein S-nitrosylation in preconditioning and postconditioning. *Experimental Biology and Medicine*, **2014**, 239, 647-62	3.7	26
87	Overexpression of the muscle-specific protein, melusin, protects from cardiac ischemia/reperfusion injury. *Basic Research in Cardiology*, **2014**, 109, 418	11.8	31
86	Catestatin increases the expression of anti-apoptotic and pro-angiogenetic factors in the post-ischemic hypertrophied heart of SHR. *PLoS ONE*, **2014**, 9, e102536	3.7	23
85	Diazoxide postconditioning induces mitochondrial protein S-nitrosylation and a redox-sensitive mitochondrial phosphorylation/translocation of RISK elements: no role for SAFE. *Basic Research in Cardiology*, **2013**, 108, 371	11.8	41
84	Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling. *Pflugers Archiv European Journal of Physiology*, **2013**, 465, 1031-40	4.6	50
83	Redox balance and cardioprotection. *Basic Research in Cardiology*, **2013**, 108, 392	11.8	97
82	Acidic infusion in early reperfusion affects the activity of antioxidant enzymes in postischemic isolated rat heart. *Journal of Surgical Research*, **2013**, 183, 111-8	2.5	9
81	Bone marrow mesenchymal stem cells increase motility of prostate cancer cells via production of stromal cell-derived factor-1 *Journal of Cellular and Molecular Medicine*, **2013**, 17, 287-92	5.6	27
80	Pharmacologically active microcarriers influence VEGF-A effects on mesenchymal stem cell survival. *Journal of Cellular and Molecular Medicine*, **2013**, 17, 192-204	5.6	37
79	Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. *Antioxidants and Redox Signaling*, **2013**, 18, 556-99	8.4	127
78	GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways. *Endocrinology*, **2013**, 154, 1624-35	4.8	26
77	Nitroglycerine and sodium trioxodinitrate: from the discovery to the preconditioning effect. *Journal of Cardiovascular Medicine*, **2013**, 14, 698-704	1.9	8
76	Postconditioning with glucagon like peptide-2 reduces ischemia/reperfusion injury in isolated rat hearts: role of survival kinases and mitochondrial KATP channels. *Basic Research in Cardiology*, **2012**, 107, 272	11.8	22
75	Cardioprotection against ischemia/reperfusion injury and chromogranin A-derived peptides. *Current Medicinal Chemistry*, **2012**, 19, 4074-85	4.3	14
74	A lipophilic nitric oxide donor and a lipophilic antioxidant compound protect rat heart against ischemia-reperfusion injury if given as hybrid molecule but not as a mixture. *Journal of Cardiovascular Pharmacology*, **2012**, 59, 241-8	3.1	8
73	Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling. *Antioxidants and Redox Signaling*, **2011**, 14, 833-50	8.4	100

72	Post-ischemic early acidosis in cardiac postconditioning modifies the activity of antioxidant enzymes, reduces nitration, and favors protein S-nitrosylation. *Pflugers Archiv European Journal of Physiology*, **2011**, 462, 219-33	4.6	25
71	Ischemia/reperfusion injury is increased and cardioprotection by a postconditioning protocol is lost as cardiac hypertrophy develops in nandrolone treated rats. *Basic Research in Cardiology*, **2011**, 106, 409-20	11.8	37
70	Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species. *World Journal of Cardiology*, **2011**, 3, 186-200	2.1	218
69	Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 300, H2308-15	5.2	56
68	Playing with cardiac "redox switches": the "HNO way" to modulate cardiac function. *Antioxidants and Redox Signaling*, **2011**, 14, 1687-98	8.4	87
67	Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats. *Basic Research in Cardiology*, **2010**, 105, 181-92	11.8	50
66	Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. *Cellular and Molecular Neurobiology*, **2010**, 30, 1171-9	4.6	55
65	Cardioprotection: a radical view Free radicals in pre and postconditioning. *Biochimica Et Biophysica Acta - Bioenergetics*, **2009**, 1787, 781-93	4.6	156
64	Physiological and pharmacological features of the novel gasotransmitter: hydrogen sulfide. *Biochimica Et Biophysica Acta - Bioenergetics*, **2009**, 1787, 864-72	4.6	137
63	Postconditioning induces an anti-apoptotic effect and preserves mitochondrial integrity in isolated rat hearts. *Biochimica Et Biophysica Acta - Bioenergetics*, **2009**, 1787, 794-801	4.6	57
62	Postconditioning cardioprotection against infarct size and post-ischemic systolic dysfunction is influenced by gender. *Basic Research in Cardiology*, **2009**, 104, 390-402	11.8	63
61	Post-ischaemic activation of kinases in the pre-conditioning-like cardioprotective effect of the platelet-activating factor. *Acta Physiologica*, **2009**, 197, 175-85	5.6	6
60	Omega 3 has a beneficial effect on ischemia/reperfusion injury, but cannot reverse the effect of stressful forced exercise. *Nutrition, Metabolism and Cardiovascular Diseases*, **2009**, 19, 20-6	4.5	14
59	Intermittent adenosine at the beginning of reperfusion does not trigger cardioprotection. *Journal of Surgical Research*, **2009**, 153, 231-8	2.5	10
58	Mesenchymal stem cell interaction with a non-woven hyaluronan-based scaffold suitable for tissue repair. *Journal of Anatomy*, **2008**, 213, 520-30	2.9	61
57	Early homing of adult mesenchymal stem cells in normal and infarcted isolated beating hearts. *Journal of Cellular and Molecular Medicine*, **2008**, 12, 507-21	5.6	24
56	The paradigm of postconditioning to protect the heart. *Journal of Cellular and Molecular Medicine*, **2008**, 12, 435-58	5.6	99
55	Nitric Oxide Synthase Function in Exercise. *Current Enzyme Inhibition*, **2008**, 4, 37-45	0.5	

54	Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. *Basic Research in Cardiology*, **2008**, 103, 368-77	11.8	56
53	Delayed preconditioning-mimetic actions of exercise or nitroglycerin do not affect haemodynamics and exercise performance in trained or sedentary individuals. *Journal of Sports Sciences*, **2007**, 25, 1393-401	3.6	11
52	Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 293, H719-27	5.2	55
51	Limited plasticity of mesenchymal stem cells cocultured with adult cardiomyocytes. *Journal of Cellular Biochemistry*, **2007**, 100, 86-99	4.7	34
50	Intermittent activation of bradykinin B2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. *Cardiovascular Research*, **2007**, 75, 168-77	9.9	112
49	Impaired central hemodynamic response and exaggerated vasoconstriction during muscle metaboreflex activation in heart failure patients. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 292, H2988-96	5.2	81
48	Nandrolone-pretreatment enhances cardiac beta(2)-adrenoceptor expression and reverses heart contractile down-regulation in the post-stress period of acute-stressed rats. *Journal of Steroid Biochemistry and Molecular Biology*, **2007**, 107, 106-13	5.1	12
47	Nitric oxide and cardiac function. *Life Sciences*, **2007**, 81, 779-93	6.8	158
46	Post-infarct heart repair with granulocyte-colony stimulating factor: is it a utopian goal?. *Cardiovascular Research*, **2006**, 71, 405-7	9.9	
45	Modulation of cardiac contractility by muscle metaboreflex following efforts of different intensities in humans. *American Journal of Physiology - Heart and Circulatory Physiology*, **2006**, 291, H3035-42	5.2	65
44	Effect of differences in post-exercise lactate accumulation in athletes' haemodynamics. *Applied Physiology, Nutrition and Metabolism*, **2006**, 31, 423-31	3	29
43	Effect of endothelins on the cardiovascular system. *Journal of Cardiovascular Medicine*, **2006**, 7, 645-52	1.9	40
42	Morphological characterization of GFP stably transfected adult mesenchymal bone marrow stem cells. *Journal of Anatomy*, **2006**, 208, 3-12	2.9	49
41	Post-conditioning reduces infarct size in the isolated rat heart: role of coronary flow and pressure and the nitric oxide/cGMP pathway. *Basic Research in Cardiology*, **2006**, 101, 168-79	11.8	103
40	Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation. *Basic Research in Cardiology*, **2006**, 101, 180-9	11.8	198
39	Myocardial protection from ischemic preconditioning is not blocked by sub-chronic inhibition of carnitine palmitoyltransferase I. *Life Sciences*, **2005**, 77, 2004-17	6.8	1
38	Rethinking the renin-angiotensin system and its role in cardiovascular regulation. *Cardiovascular Drugs and Therapy*, **2005**, 19, 77-87	3.9	47
37	Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 288, H2512-20	5.2	39

36	F0F1 ATP synthase activity is differently modulated by coronary reactive hyperemia before and after ischemic preconditioning in the goat. *American Journal of Physiology - Heart and Circulatory Physiology*, **2004**, 287, H2192-200	5.2	22
35	Exercise-induced and nitroglycerin-induced myocardial preconditioning improves hemodynamics in patients with angina. *American Journal of Physiology - Heart and Circulatory Physiology*, **2004**, 287, H235-42	5.2	43
34	Endothelial cytochrome P450 contributes to the acetylcholine-induced cardiodepression in isolated rat hearts. *Acta Physiologica Scandinavica*, **2004**, 182, 11-20		2
33	Haemodynamic responses following intermittent supramaximal exercise in athletes. *Experimental Physiology*, **2004**, 89, 665-74	2.4	29
32	In vitro and in vivo studies of F(0)F(1)ATP synthase regulation by inhibitor protein IF(1) in goat heart. *Biochimica Et Biophysica Acta - Bioenergetics*, **2004**, 1659, 52-62	4.6	39
31	Antioxidant Properties of Nitric Oxide in Cellular Physiological and Pathophysiological Mechanisms. The Implications of Biological Balance between NO and Oxidative Stress. *Current Medicinal Chemistry Anti-inflammatory & Anti-allergy Agents*, **2004**, 3, 181-188		6
30	Role of the fuel utilized by tissues on coronary vessel response to physical stimuli in isolated rat hearts. *Physiological Research*, **2004**, 53, 27-34	2.1	1
29	Muscle metaboreflex-induced increases in stroke volume. *Medicine and Science in Sports and Exercise*, **2003**, 35, 221-8; discussion 229	1.2	97
28	Orthogonal properties of the redox siblings nitroxyl and nitric oxide in the cardiovascular system: a novel redox paradigm. *American Journal of Physiology - Heart and Circulatory Physiology*, **2003**, 285, H2264-76	5.2	75
27	Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. *Free Radical Biology and Medicine*, **2003**, 34, 33-43	7.8	169
26	Differential biological effects of products of nitric oxide (NO) synthase: it is not enough to say NO. *Life Sciences*, **2003**, 73, 2137-49	6.8	64
25	Coronary endothelial dysfunction after ischemia and reperfusion and its prevention by ischemic preconditioning. *Italian Heart Journal: Official Journal of the Italian Federation of Cardiology*, **2003**, 4, 383-94		10
24	Fatty acids are important for the Frank-Starling mechanism and Gregg effect but not for catecholamine response in isolated rat hearts. *Acta Physiologica Scandinavica*, **2002**, 176, 167-76		7
23	Ischemic preconditioning changes the pattern of coronary reactive hyperemia regardless of mitochondrial ATP-sensitive K(+) channel blockade. *Life Sciences*, **2002**, 71, 2299-309	6.8	4
22	Mitochondrial ATP-sensitive channel opener does not induce vascular preconditioning, but potentiates the effect of a preconditioning ischemia on coronary reactive hyperemia in the anesthetized goat. *Pflugers Archiv European Journal of Physiology*, **2001**, 443, 166-74	4.6	4
21	Role of calcium-sensitive K(+) channels and nitric oxide in in vivo coronary vasodilation from enhanced perfusion pulsatility. *Circulation*, **2001**, 103, 119-24	16.7	40
20	Ischemic preconditioning: from the first to the second window of protection. *Life Sciences*, **2001**, 69, 1-15	6.8	84
19	Comparison between the effects of pentobarbital or ketamine/nitrous oxide anesthesia on metabolic and endothelial components of coronary reactive hyperemia. *Life Sciences*, **2001**, 69, 729-38	6.8	10

18	Model-based assessment of pressure and flow-dependent coronary responses following abrupt pressure drops. *Computers in Biology and Medicine*, **2000**, 30, 111-26	7	1
17	Reversal of glibenclamide-induced coronary vasoconstriction by enhanced perfusion pulsatility: possible role for nitric oxide. *Cardiovascular Research*, **2000**, 45, 1001-9	9.9	6
16	Ischaemic preconditioning changes the pattern of coronary reactive hyperaemia in the goat: role of adenosine and nitric oxide. *Cardiovascular Research*, **1999**, 42, 57-64	9.9	31
15	Regulation of basal myocardial function by NO. *Cardiovascular Research*, **1999**, 44, 223-4	9.9	1
14	Specificity of synergistic coronary flow enhancement by adenosine and pulsatile perfusion in the dog. *Journal of Physiology*, **1999**, 520 Pt 1, 271-80	3.9	9
13	The effects of ischemic preconditioning on resting coronary flow and reactive hyperemia: involvement of A1 adenosine receptors. *Life Sciences*, **1999**, 64, 1071-8	6.8	8
12	New insights into nitric oxide and coronary circulation. *Life Sciences*, **1999**, 65, 2167-74	6.8	22
11	Systolic coronary flow impediment in the dog: role of ventricular pressure and contractility. *Experimental Physiology*, **1998**, 83, 821-31	2.4	8
10	The Gaboon viper, Bitis gabonica: hemorrhagic, metabolic, cardiovascular and clinical effects of the venom. *Life Sciences*, **1997**, 61, 763-9	6.8	23
9	Myocardial, neural and vascular aspects of ischemic preconditioning. *Life Sciences*, **1996**, 59, 1185-92	6.8	15
8	The heart rate after inhibition of nitric oxide release in the anaesthetized dog. *General Pharmacology*, **1996**, 27, 695-9		5
7	The role of nitric oxide in the initiation and in the duration of some vasodilator responses in the coronary circulation. *Pflugers Archiv European Journal of Physiology*, **1995**, 430, 96-104	4.6	12
6	Control of coronary blood flow by endothelial release of nitric oxide. *Clinical and Experimental Pharmacology and Physiology*, **1994**, 21, 783-9	3	12
5	The effect of the inhibition of the endothelial release of nitric oxide on coronary reactive hyperaemia in the anaesthetized dog. *Life Sciences*, **1994**, 54, 791-8	6.8	9
4	The mechanical and electrical effects of rhinoceros viper (Bitis nasicornis) venom on the isolated perfused guinea pig heart and atrial preparations. *Life Sciences*, **1991**, 49, 1539-48	6.8	1
3	Acidotic effect of gaboon viper (Bitis gabonica) venom in the urethane-anaesthetized rat. *General Pharmacology*, **1991**, 22, 199-202		1
2	The haemodynamic effect of Bitis nasicornis (rhinoceros horned viper) venom. *General Pharmacology*, **1991**, 22, 203-6		3
1	Acid-base, plasma lactate and glucose changes in the rabbit following administration of Gaboon viper (Bitis gabonica) venom. *Life Sciences*, **1989**, 45, 1893-901	6.8	3